ZNTL | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 23%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

19.35%

1 Month

26.50%

3 Months

111.43%

6 Months

98.66%

1 Year

51.79%

2 Year

-79.98%

Key data

Stock price

$2.96

P/E Ratio

0.00

DAY RANGE

$2.85 - $3.13

EPS

-$2.95

52 WEEK RANGE

$1.01 - $3.95

52 WEEK CHANGE

$63.54

MARKET CAP

108.925 M

YIELD

N/A

SHARES OUTSTANDING

72.251 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-06-2025

BETA

1.76

PUBLIC FLOAT

AVERAGE 10 VOLUME

$850,655

AVERAGE 30 VOLUME

$699,348

Company detail

CEO: Kimberly L. Blackwell
Region: US
Website: zentalis.com
Employees: 160
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.

ZNTL - Zentalis Pharmaceuticals Inc